View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
October 20, 2021updated 11 Jul 2022 9:48am

Asia-Pacific has seen the largest growth in cardiovascular trials over the past decade

We've analysed 10 years' worth of clinical trials data from GlobalData to pick out key geographic trends.

By GlobalData Healthcare

The Asia-Pacific region has seen a 38% increase in the number of cardiovascular trials taking place over the past decade, the largest increase for any region worldwide.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The region now ranks in first for the total number of trials taking place, compared to its third placed ranking in 2010.

These figures come from GlobalData’s extensive clinical trials database, which seeks to track the number of clinical trials taking place in countries around the world, in numerous therapy areas.

Asia-Pacific

The Asia-Pacific region saw the biggest increase in cardiovascular related trials.

Between 2010 and 2020, there was a 38% increase in the number of trials taking place.

In 2020, the largest proportion of trials in the region took place in China with 60.6% of all trials in the region taking place there.

South Korea and India had the next largest percentage of trials taking place in the region with 8.4% and 7.6%, respectively.

Middle East

The Middle East saw a 33% increase in the number of cardiovascular trials taking place.

Iran saw the largest amount of trials taking place, in 2020, at 81.1%.

Trials in Israel and Saudi Arabia also made up a large proportion of the trials taking place with 14.4% and 3.8%, respectively.

Africa

Africa saw a 14% increase in the number trials taking place.

Egypt, South Africa and Tunisia made up the most trials in the region, with 81.8%, 6.1% and 3%, respectively.

Europe

Europe saw a 15% decrease in cardiovascular related trials taking place.

Russia saw the largest percentage of trials taking place in the region at 11.2%.

France and the United Kingdom also made up a significant proportion of the trials taking place.

North America

North America saw a decrease in the number of cardiovascular trials.

The region saw a 16% decrease in the number of trials.

The United States made up 72.8% the largest proportion of trials taking place in the region.

Canada and Mexico also made up a large amount of the trials taking place with 21.5% and 5.7%, respectively.

South and Central America

South and Central America saw the biggest decrease in cardiovascular trials.

The number of trials in the region fell by 42% between 2010 and 2020.

Brazil saw the largest percentage of trials taking place in the region with 57.1%.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology